Blinatumomab for Previously Treated Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukaemia (TA450)

Technology Appraisal Guidance No. 450

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults, only if the company provides it with the discount agreed in the patient access scheme.


A copy of the full document and background is available on the Internet at www.nice.org.uk/guidance/ta450

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia.
Issue Date: June 2017


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

No need to restrict dietary vitamin K intake in patients on warfarin, say researchers

No need to restrict dietary vitamin K intake in patients on warfarin, say researchers

Increasing dietary vitamin K intake may be beneficial...

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

A careful stepwise approach is needed when reducing...

Prescribers advised not to use newer anticoagulants in patients with antiphospholipid syndrome
Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...